Please login to the form below

Not currently logged in

Bone Therapeutics looks to Pfizer for clinical head

Guy Heynen has 35 years of industry experience

Bone Therapeutics, the regenerative therapy company for bone diseases and orthopaedics, has named Guy Heynen as its chief clinical and regulatory officer.

Heynen will support the firm as it progresses its pipeline of regenerative bone disease and orthopaedic therapies through clinical development and commercialisation.

Commenting on his appointment, Heynen said: “I am privileged to be joining the company at such an exciting time in its development and I look forward to working with the team to advance its innovative products towards commercialisation.”

Heynen is a specialist in rheumatology and immunology, with over 35 years of experience in medical and regulatory affairs at local, regional and international levels.

He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's disease drug Aricept and medical team leader for its anti-inflammatory drug franchise based in New York.

CEO of Bone Therapeutics Enrico Bastianello said: “Heynen's understanding of clinical operations and regulatory affairs will be an invaluable asset to Bone Therapeutics as we move forward to advance out innovative late-stage pipeline of regenerative medicines.

“His long-standing experience within major pharmaceutical companies around the world will be key in preparing to bring our products to market and supporting our development on a global scale.”

Heynen also serves on the boards of Euroscreen, Progenosis and as an advisor for Promethera Biosciences. He will remain a regional medical monitor for Pfizer.

24th December 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....